We participated in the AACR conference with three distinct poster presentations.

  1. Targeting PDE4D reinstates toxic PARP trapping via cAMP-ROS-DNA damage axis and restores the efficacy of standard of care in treatment-refractory ER+ breast cancer.
  2. Rewiring collagen architecture using a highly potent bi-thiazole inhibitor of LOX mediates chemosensitization in triple-negative breast cancer.
  3.  Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer.
Categories: News


Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *